Here are the 10-Q quarterly reports from Tourmaline Bio, Inc. (TRML) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TRML and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TRML filings page.
Tourmaline Bio, Inc. (TRML) reported unaudited results for the quarter ended June 30, 2025 showing continued investment in clinical development of pacibekitug and a solid liquidity position. The company held $256.4 million in cash, cash equivalents and investments and reported a net loss of $46.1 million for the six months ended June 30, 2025, widening from $30.8 million a year earlier due to higher research and development spending.
Research and development expenses rose to $39.9 million for the six-month period, driven by higher clinical trial and toxicology costs as Tourmaline advanced the TRANQUILITY and spiriTED programs. The company disclosed positive Phase 2 TRANQUILITY topline results showing rapid, deep and durable reductions in hs-CRP with quarterly dosing and reported comparable adverse event rates to placebo through the data extract date. Management expects existing funds to support operations into the second half of 2027 and plans further development including a potential Phase 3 cardiovascular outcomes trial and a Phase 2 proof-of-concept study in abdominal aortic aneurysm.